1. Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4+ T Cells
- Author
-
Dorian B. McGavern, Yongmei Zhao, Monika Mehta, Rémy Bosselut, Samira Tamoutounour, Thomas Ciucci, Bao Tran, Assaf Magen, Sridhar Hannenhalli, and Jia Nie
- Subjects
CD4-Positive T-Lymphocytes ,0301 basic medicine ,medicine.medical_treatment ,CD8-Positive T-Lymphocytes ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,0302 clinical medicine ,Cancer immunotherapy ,Cell Line, Tumor ,Neoplasms ,Tumor Microenvironment ,medicine ,Animals ,Humans ,Cytotoxic T cell ,Lymph node ,lcsh:QH301-705.5 ,Tumor-infiltrating lymphocytes ,Effector ,Immunotherapy ,Th1 Cells ,Mice, Inbred C57BL ,030104 developmental biology ,MRNA Sequencing ,medicine.anatomical_structure ,lcsh:Biology (General) ,Interferon Type I ,Viruses ,Cancer research ,Transcriptome ,030217 neurology & neurosurgery ,CD8 - Abstract
SUMMARY Most current tumor immunotherapy strategies leverage cytotoxic CD8+ T cells. Despite evidence for clinical potential of CD4+ tumor-infiltrating lymphocytes (TILs), their functional diversity limits our ability to harness their activity. Here, we use single-cell mRNA sequencing to analyze the response of tumor-specific CD4+ TILs and draining lymph node (dLN) T cells. Computational approaches to characterize subpopulations identify TIL transcriptomic patterns strikingly distinct from acute and chronic anti-viral responses and dominated by diversity among T-bet-expressing T helper type 1 (Th1)-like cells. In contrast, the dLN response includes T follicular helper (Tfh) cells but lacks Th1 cells. We identify a type I interferon-driven signature in Th1-like TILs and show that it is found in human cancers, in which it is negatively associated with response to checkpoint therapy. Our study provides a proof-of-concept methodology to characterize tumor-specific CD4+ T cell effector programs. Targeting these programs should help improve immunotherapy strategies., In Brief CD4+ T cells contribute to immune responses to tumors, but their functional diversity has hampered their utilization in clinical settings. Magen et al. use single-cell RNA sequencing to dissect the heterogeneity of CD4+ T cell responses to tumor antigens and reveal molecular divergences between anti-tumor and anti-viral responses., Graphical Abstract
- Published
- 2019